122 related articles for article (PubMed ID: 30881510)
1. Phase I study of preoperative chemoradiotherapy with sequential oxaliplatin and irinotecan with S-1 for locally advanced rectal cancer.
Fujikawa H; Toiyama Y; Inoue Y; Omura Y; Ide S; Kitajima T; Yasuda H; Okugawa Y; Okita Y; Yoshiyama S; Hiro J; Kobayashi M; Ohi M; Araki T; Kusunoki M
Oncol Lett; 2019 Apr; 17(4):3930-3936. PubMed ID: 30881510
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
Ishihara S; Matsusaka S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shinbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
Radiat Oncol; 2015 Jan; 10():24. PubMed ID: 25612635
[TBL] [Abstract][Full Text] [Related]
3. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Sato T; Hayakawa K; Tomita N; Noda M; Kamikonya N; Watanabe T; Kato D; Sakai Y; Hiraoka M; Shimada M; Ikushima H; Baba H; Oya N; Oya M; Nemoto-Murofushi K; Takeuchi M; Watanabe M
Radiother Oncol; 2016 Aug; 120(2):222-7. PubMed ID: 27317556
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
Sato T; Kokuba Y; Koizumi W; Hayakawa K; Okayasu I; Watanabe M
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1442-7. PubMed ID: 17855009
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
Matsusaka S; Ishihara S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
Radiother Oncol; 2015 Aug; 116(2):209-13. PubMed ID: 26337743
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
10. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
[TBL] [Abstract][Full Text] [Related]
12. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer.
Kudo T; Takemasa I; Hata T; Sakai D; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Satoh T; Mizushima T; Mori M; Doki Y
Oncology; 2019; 97(4):211-216. PubMed ID: 31266024
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
15. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
16. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
19. [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Xiao L; Yu X; Zhu Y; Xiao W; Zeng Z; Liu M; Zhang R; Gao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):769-75. PubMed ID: 27452754
[TBL] [Abstract][Full Text] [Related]
20. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]